Replies to post #34934 on Biotech Values

[go seek]

How do you see the HGSI / NVS collaboration (phase 3 start)
visa ve development of NM283?

Certainly NVS is doing more than spinning the wheel of fortune for potential drug winners in HCV treatment.

At the same time, how many potential $500M collaborations (given milestones) can NVS realistically afford to enter?

ie. does the fact NVS is dealing w/ HGSI diminish the shine on NM283?

Happy October to all!

[DewDiligence]

HGSI initiates phase-3 Albuferon trial in genotype-1 HCV. The companion phase-3 trial in genotype-2 and genotype-3 is slated to start in 1H07 (which probably means 2Q07).

http://biz.yahoo.com/prnews/061219/nytu060.html?.v=78

Please see #msg-13781766 for a description of the phase-3 Albuferon program.